Implementation of Germline Testing for Prostate Cance Consensus Conference 2019

Journal of Clinical Oncology

38, 2798-2811

DOI: 10.1200/jco.20.00046

Citation Report

#	Article	IF	Citations
1	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. JCO Oncology Practice, 2020, 16, 811-819.	1.4	35
2	Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments. European Urology Oncology, 2022, 5, 587-600.	2.6	8
3	Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementationâœ°,âœ°âœ°. Cancer Treatment and Research Communications, 2020, 25, 100212.	0.7	20
4	BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications. Journal of Oncology, 2020, 2020, 1-7.	0.6	58
5	Somatic Testing and Germline Genetic Status: Implications for Cancer Treatment Decisions and Genetic Counseling. Current Genetic Medicine Reports, 2020, 8, 109-119.	1.9	0
6	Bringing Greater Accuracy to Europeâ€™s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. Biomedicine Hub, 2020, 5, 1-42.	0.4	15
7	Diagnostic value of retrospectively fused 64CuCl2 PET/MRI in biochemical relapse of prostate cancer: comparison with fused 18F-Choline PET/MRI, 64CuCl2 PET/CT, 18F-Choline PET/CT, and mpMRI. Abdominal Radiology, 2020, 45, 3896-3906.	1.0	8
8	Findings from a Genetic Sequencing Investigation of Men with Familial and Aggressive Prostate Cancer. European Urology, 2021, 79, 362-363.	0.9	2
9	Current and emerging therapies for localized high-risk prostate cancer. Expert Review of Anticancer Therapy, 2021, 21, 267-282.	1.1	3
10	PARP Inhibitors and Prostate Cancer: To Infinity and BeyondBRCA. Oncologist, 2021, 26, e115-e129.	1.9	51
11	Genetic predisposition to prostate cancer: an update. Familial Cancer, 2022, 21, 101-114.	0.9	18
12	Clinical implications of genomic alterations in metastatic prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 310-322.	2.0	12
13	SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). Clinical and Translational Oncology, 2021, 23, 969-979.	1.2	18
14	Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. Journal of Pathology: Clinical Research, 2021, 7, 311-325.	1.3	19
15	Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer. European Urology Oncology, 2021, 4, 1-9.	2.6	27
16	Prostate cancer. Nature Reviews Disease Primers, 2021, 7, 9.	18.1	434
17	Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease. Cancers, 2021, 13, 760.	1.7	22
18	Novel Strategies for Treating Castration-Resistant Prostate Cancer. Biomedicines, 2021, 9, 339.	1.4	14

#	Article	IF	Citations
19	Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion. JCO Precision Oncology, 2021, 5, 533-542.	1.5	6
20	Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: Up-date of the Italian Society of Integrated Diagnostic in Urology. Archivio Italiano Di Urologia Andrologia, 2021, 93, 92-100.	0.4	9
21	How I Treat Metastatic Hormone-Sensitive Prostate Cancer?. Indian Journal of Medical and Paediatric Oncology, 2021, 42, 100-107.	0.1	0
22	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. European Journal of Cancer, 2021, 146, 30-47.	1.3	81
23	Epidemiology and genomics of prostate cancer in Asian men. Nature Reviews Urology, 2021, 18, 282-301.	1.9	111
24	Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment. Oncologist, 2021, 26, 537-548.	1.9	8
26	Using a Genomics Taxonomy: Facilitating Patient Care Safety and Quality in the Era of Precision Oncology. Clinical Journal of Oncology Nursing, 2021, 25, 205-209.	0.3	0
27	Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management. Cancers, 2021, 13, 2154.	1.7	13
29	Barriers and facilitators of germline genetic evaluation for prostate cancer. Prostate, 2021, 81, 754-764.	1.2	19
30	Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice. JCO Precision Oncology, 2021, 5, 884-895.	1.5	21
31	Prognostic Value of BRCA1 and BRCA2 Gene Mutations in Prostate Cancer: a Literature Review. KreativnaÃ¢ HirurgiÃ¢ I OnkologiÃ¢, 2021, 11, 183-187.	0.1	1
32	Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology. Expert Opinion on Therapeutic Targets, 2021, 25, 329-333.	1.5	39
34	The Hammer and Nail Phenomenon: The Expanding Acceptance of Active Surveillance in Urologic Oncology.. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 281-285.	0.8	1
35	Prostate cancer risk variants of the HOXB genetic locus. Scientific Reports, 2021, 11, 11385.	1.6	6
36	First international workshop of the ATM and cancer risk group (4-5 December 2019). Familial Cancer, 2022, 21, 211-227.	0.9	10
37	Recent Insights on Genetic Testing in Primary Prostate Cancer. Molecular Diagnosis and Therapy, 2021, 25, 425-438.	1.6	3
38	Clinical utility of pathology data: prostate and kidney cancer. Diagnostic Histopathology, 2021, 27, 297-304.	0.2	3
39	B2B: Prostate Cancer. SociÃ©tÃ© Internationale D'urologie Journal, 2021, 2, S30-S50.	0.2	0

#	Article	IF	Citations
40	Observed evidence for guidelineâ€recommended genes in predicting prostate cancer risk from a large populationâ€based cohort. Prostate, 2021, 81, 1002-1008.	1.2	10
41	Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs. JCO Precision Oncology, 2021, 5, 1377-1386.	1.5	5
42	Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. Cancer, 2021, 127, 3957-3966.	2.0	11
43	Genetic Contribution to Metastatic Prostate Cancer. Urologic Clinics of North America, 2021, 48, 349-363.	0.8	0
44	Familial Risks and Proportions Describing Population Landscape of Familial Cancer. Cancers, 2021, 13, 4385.	1.7	20
45	Overview of Prostate Cancer Genetic Testing. Urologic Clinics of North America, 2021, 48, 279-282.	0.8	0
46	Clinical Multigene Testing for Prostate Cancer. Urologic Clinics of North America, 2021, 48, 297-309.	0.8	2
48	Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions. Oncotarget, 2021, 12, 1600-1614.	0.8	14
49	Genetic Testing Guidelines and Education of Health Care Providers Involved in Prostate Cancer Care. Urologic Clinics of North America, 2021, 48, 311-322.	0.8	2
50	Genetic Counseling for Men with Prostate Cancer. Urologic Clinics of North America, 2021, 48, 323-337.	0.8	0
51	Genetically Informed Prostate Cancer Screening. Urologic Clinics of North America, 2021, 48, 373-386.	0.8	1
52	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. European Urology Oncology, 2021, 4, 570-579.	2.6	38
53	Prostate Cancer Genetics: The Urologic Research Promissory Note Is Being Cashed. Urologic Clinics of North America, 2021, 48, xi-xii.	0.8	0
54	Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate. BJU International, 2022, 129, 345-355.	1.3	18
55	Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness. Urologic Clinics of North America, 2021, 48, 339-347.	0.8	5
56	Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC). Biomedicines, 2021, 9, 1247.	1.4	22
57	Surgery for oligometastatic prostate cancer: Where are we going?. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2021, 45, 479-480.	0.2	0
58	Gaps in Public Awareness About BRCA and Genetic Testing in Prostate Cancer: Social Media Landscape Analysis. JMIR Cancer, 2021, 7, e27063.	0.9	10

#	Article	IF	Citations
60	Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic. International Journal of Molecular Sciences, 2021, 22, 9783.	1.8	35
61	Asesoramiento genÃ©tico en cÃ¡ncer de prÃ³stata: Â¿cÃ³mo implementarlo en la prÃ¡ctica clÃnica diaria?. Actas UrolÃ³gicas EspaÃ±olas, 2021, 45, 8-20.	0.3	2
62	Genetic counseling in prostate cancer: How to implement it in daily clinical practice?. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2021, 45, 8-20.	0.2	1
63	Genetics in prostate cancer: implications for clinical practice. Current Opinion in Supportive and Palliative Care, 2021, 15, 241-246.	0.5	4
64	Updates in Prostate Cancer Research and Screening in Men at Genetically Higher Risk. Current Genetic Medicine Reports, 2021, 9, 47-58.	1.9	5
65	Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer. European Urology, 2022, 81, 559-567.	0.9	17
68	Contemporary Grading of Prostate Cancer: The Impact of Grading Criteria and the Significance of the Amount of Intraductal Carcinoma. Cancers, 2021, 13, 5454.	1.7	6
69	Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?. Cancers, 2021, 13, 5464.	1.7	1
70	Genetic Mutations Associated With Prostate Cancer and Normal Serum PSA and DRE-Implications for Prostate Cancer Screening and Management: NYU Case of the Month, November 2020. Reviews in Urology, 2020, 22, 177-181.	0.9	0
71	Inherited Mutations in Chinese Men With Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 54-62.	2.3	13
72	BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations. International Journal of Molecular Sciences, 2021, 22, 12628.	1.8	44
73	Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer. Cancers, 2021, 13, 5697.	1.7	10
74	Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice. Clinical Genitourinary Cancer, 2022, 20, e104-e113.	0.9	7
75	Disparities in germline testing among racial minorities with prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 403-410.	2.0	22
76	Advances in urologic oncology â€œOncoUrology Forum Special Editionâ€: The best of 2020. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2021, , .	0.2	0
77	Inherited TP53 Variants and Risk of Prostate Cancer. European Urology, 2022, 81, 243-250.	0.9	40
78	Analysis of the Role of Comprehensive Treatment Model in the Treatment of Prostate Cancer. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-7.	0.7	1
79	Prevalence and Spectrum of Predisposition Genes With Germline Mutations Among Chinese Patients With Bowel Cancer. Frontiers in Genetics, 2021, 12, 755629.	1.1	1

#	Article	IF	Citations
80	Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy. JNCI Cancer Spectrum, 2022, 6, pkac001.	1.4	3
82	Genetic Evaluation for Hereditary Cancer Syndromes Among African Americans: A Critical Review. Oncologist, 2022, 27, 285-291.	1.9	10
83	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer and Prostatic Diseases, 2022, 25, 755-761.	2.0	14
84	Genetic testing in prostate cancer management: Considerations informing primary care. Ca-A Cancer Journal for Clinicians, 2022, 72, 360-371.	157.7	15
85	Implications of DNA damage repair alterations for the management of prostate cancer. Current Opinion in Urology, 2022, 32, 302-310.	0.9	1
86	Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer. World Journal of Urology, 2022, , 1.	1.2	0
87	Hereditary cancer risk assessment and genetic testing in the community urology practice setting. Prostate, 2022, , .	1.2	0
88	TP53: Another Piece of the Prostate Cancer Genetics Puzzle. European Urology, 2022, 81, 251-252.	0.9	1
89	Challenges in breast cancer genetic testing. A call for novel forms of multidisciplinary care and long-term evaluation. Critical Reviews in Oncology/Hematology, 2022, 176, 103642.	2.0	4
90	PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers. Journal of Clinical Medicine, 2022, 11, 1734.	1.0	5
91	Bisphenol S promotes the progression of prostate cancer by regulating the expression of COL1A1 and COL1A2. Toxicology, 2022, 472, 153178.	2.0	19
93	Germline testing and genetic counselling in prostate cancer. Nature Reviews Urology, 2022, 19, 331-343.	1.9	18
94	Germline pathogenic variants in unselected Korean men with prostate cancer. Investigative and Clinical Urology, 2022, 63, 294.	1.0	3
95	Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients. International Journal of Molecular Sciences, 2022, 23, 4709.	1.8	13
96	Precision intervention for prostate cancer: Re-evaluating who is at risk. Cancer Letters, 2022, 538, 215709.	3.2	9
97	Comprehensive analysis of emerging flame retardants, a risk factor to prostate cancer?. Ecotoxicology and Environmental Safety, 2022, 239, 113627.	2.9	2
98	Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer. International Journal of Biochemistry and Cell Biology, 2022, 147, 106230.	1.2	2
99	Two-year profile of the records of patients referred to Adana city hospital urology clinic due to PSA high in primary care: a retrospective review. Journal of Health Sciences and Medicine, 2022, 5, 726-731.	0.0	0

#	Article	IF	Citations
100	Germline genetics of prostate cancer. Prostate, 2022, 82, .	1.2	8
101	Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing. JCO Precision Oncology, 2022, , .	1.5	7
102	Poster Session 9: Oncology â€“ Prostate. Canadian Urological Association Journal, 2022, 16, .	0.3	0
103	Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in Canada. Canadian Urological Association Journal, 2022, 16, .	0.3	3
104	Cribriform Patterned Lesions in the Prostate Gland with Emphasis on Differential Diagnosis and Clinical Significance. Cancers, 2022, 14, 3041.	1.7	7
105	Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Contemporary Clinical Trials, 2022, 119, 106821.	0.8	4
106	Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D. Breast, 2022, 65, 32-40.	0.9	25
107	An appraisal of genetic testing for prostate cancer susceptibility. Npj Precision Oncology, 2022, 6, .	2.3	6
108	<scp>WHO</scp> Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. Histopathology, 2022, 81, 447-458.	1.6	10
109	Guidelines on Germline Testing for Urologic Tumor Syndromes. European Urology Focus, 2022, 8, 670-673.	1.6	4
110	Genetic Testing and Its Clinical Application in Prostate Cancer Management: Consensus Statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology. Frontiers in Oncology, 0, 12, .	1.3	2
111	Oleocanthal Attenuates Metastatic Castration-Resistant Prostate Cancer Progression and Recurrence by Targeting SMYD2. Cancers, 2022, 14, 3542.	1.7	5
112	Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families. Journal of Community Genetics, 0, , .	0.5	0
113	Novel Germline Mutations in a Cohort of Men with Familial Prostate Cancer. Cancers, 2022, 14, 3623.	1.7	1
114	Novel germline mutations for active surveillance and imaging strategies in prostate cancer. Current Opinion in Urology, 2022, 32, 456-461.	0.9	1
115	The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organsâ€”Part B: Prostate and Urinary Tract Tumors. European Urology, 2022, 82, 469-482.	0.9	71
116	What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib. Frontiers in Oncology, 0, 12, .	1.3	2
117	Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer. British Journal of Cancer, 2022, 127, 1680-1690.	2.9	13

#	Article	IF	Citations
118	Blood Prostate-specific Antigen by Volume of Benign, Gleason Pattern 3 and 4 Prostate Tissue. Urology, 2022, 170, 154-160.	0.5	3
119	Family History of Prostate and Breast Cancer Integrated with a Polygenic Risk Score Identifies Men at Highest Risk of Dying from Prostate Cancer before Age 75 Years. Clinical Cancer Research, 2022, 28, 4926-4933.	3.2	2
120	The Inexorable March of Prostate Cancer Research. Urologic Clinics of North America, 2022, , .	0.8	0
121	Comparison of three guidelines for screening, diagnosis and staging of prostate cancer in the USA and Europe. Journal of Cancer Prevention & Current Research, 2021, 12, 65-72.	0.1	0
122	Initial outcomes and insights from a novel highâ€risk prostate cancer screening clinic. Prostate, 0, , .	1.2	0
124	Molecular Genetics of Prostate Cancer and Role of Genomic Testing. Surgical Pathology Clinics, 2022, 15, 617-628.	0.7	5
125	The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk. BMC Urology, 2022, 22, .	0.6	1
126	Examining interprofessional collaboration in oncogenetic service delivery models for hereditary cancers: a scoping review protocol. BMJ Open, 2022, 12, e066802.	0.8	1
127	A review of the cost-effectiveness of genetic testing for germline variants in familial cancer. Journal of Medical Economics, 2023, 26, 19-33.	1.0	4
128	Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention. European Urology, 2023, 83, 241-248.	0.9	16
129	Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer. JCO Precision Oncology, 2023, , .	1.5	5
130	A potassium-chloride co-transporter promotes tumor progression and castration resistance of prostate cancer through m6A reader YTHDC1. Cell Death and Disease, 2023, 14, .	2.7	6
131	Prostate Pathology: What is New in the 2022 WHO Classification of Urinary and Male Genital Tumors?. Pathologica, 0, , 1-16.	1.3	2
132	Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer. JCO Oncology Practice, 2023, 19, e773-e783.	1.4	4
133	Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nature Reviews Urology, 2023, 20, 205-216.	1.9	10
134	How the Analysis of the Pathogenetic Variants of DDR Genes Will Change the Management of Prostate Cancer Patients. International Journal of Molecular Sciences, 2023, 24, 674.	1.8	4
135	Understanding cancer predisposition in Singapore: What's next. Singapore Medical Journal, 2023, 64, 37.	0.3	2
136	Prostate Cancer: Advances in Genetic Testing and Clinical Implications. Uro, 2023, 3, 91-103.	0.3	1

#	Article	IF	Citations
137	Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients. Journal of Urology, 2023, 209, 918-927.	0.2	1
138	An approach to genetic testing in patients with metastatic castration-resistant prostate cancer in Singapore. Annals of the Academy of Medicine, Singapore, 2023, 52, 135-148.	0.2	1
142	Guidelines for genetic testing in prostate cancer: a scoping review. Prostate Cancer and Prostatic Diseases, 0, , .	2.0	5
152	Pathology and Staging. , 2023, , 209-227.		0
163	Germline Mutations and Ancestry in Prostate Cancer. Current Oncology Reports, 2024, 26, 175-180.	1.8	0